Amendment No. 1 to the Amended and Restated Executive Employment Agreement by and between Finch Therapeutics Group, Inc. and Joseph Vittiglio, dated as of March 18, 2021
Exhibit 10.21
AMENDMENT NO. 1
TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
This AMENDMENT NO. 1 TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “New Amendment”) is made as of March 18, 2021, by and between Finch Therapeutics Group, Inc., a Delaware corporation (“FTG”, together with all subsidiaries and affiliates hereinafter referred to as the “Company”), and Joseph Vittiglio (the “Executive”) This New Amendment shall amend that certain AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, dated as of March 12, 2021 (the “Prior Amendment”), by and between the Company and the Executive.
RECITALS
WHEREAS, the Prior Amendment amended that certain Employment Agreement, dated on or about December 7, 2020, by and between the Company and the Executive (the “Employment Agreement”); and
WHEREAS, the vesting commencement date set forth in the Prior Amendment was mis-stated due to an administrative error; and
WHEREAS, the parties desire to amend the Prior Amendment to reflect the true intention of the Company and the Executive, as set forth herein.
NOW, THEREFORE, for good and valuable consideration, the sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows:
IN WITNESS WHEREOF, the undersigned hereby executes this New Amendment as of the date first above written.
FINCH THERAPEUTICS GROUP, INC.
By: /s/ Mark Smith
Name: Mark Smith Title: CEO
EXECUTIVE:
/s/ Joseph Vittiglio
Name: Joseph Vittiglio